Evidence map›Paper›PMID 41354147›Full record

ArticleJournal of molecular biology2026

Structure-based Discovery of a Non-competitive FTO Inhibitor Bound to a Cryptic Site at the Domain Interface.

Aayushi Singh, Francesco Pettini, Beatrice Gianibbi, Sayan Das, Donatella Barisani, Jeffrey A Purslow, Simone Furini, Ottavia Spiga, Vincenzo Venditti

Abstract read
In one paragraph

Article in Journal of molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Biomolecular NMR assignments · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aayushi SinghDepartment of Chemistry, Iowa State University, Ames, IA, USA.
Francesco PettiniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Beatrice GianibbiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Sayan DasDepartment of Chemistry, Iowa State University, Ames, IA, USA.
Donatella BarisaniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Jeffrey A PurslowDepartment of Chemistry, Iowa State University, Ames, IA, USA.
Simone FuriniDepartment of Electrical, Electronic and Information Engineering "Guglielmo Marconi", University of Bologna, Cesena, Italy.
Ottavia SpigaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy; Center for Science and Technology, Joint Laboratory of the University of Siena and the Grosseto University Foundation, Italy. Electronic address: ottavia.spiga@unisi.it.
Vincenzo VendittiDepartment of Chemistry, Iowa State University, Ames, IA, USA; Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011, USA. Electronic address: venditti@iastate.edu.

Funding

Atomic-level characterization of self-regulatory mechanisms in large multidomain enzymesR35GM133488 · NIGMS · IOWA STATE UNIVERSITY · PI Vincenzo Venditti · 2019 to 2026
$2.9M
Console and Probe Upgrade for a 700 MHz NMR SpectrometerS10OD032235 · OD · IOWA STATE UNIVERSITY · PI ANDREOTTI, AMY H · 2022 to 2022
$1.0M
NIGMS NIH HHS R35 GM133488NIH HHS S10 OD032235
6 · The paper itself

Abstract

The fat mass and obesity-associated fatso (FTO) protein is a member of the AlkB family of dioxygenases whose overexpression links to several metabolic diseases, including obesity, type 2 diabetes, Alzheimer's, and various types of cancer. FTO is an important target for pharmaceutical research, and several selective and non-selective competitive inhibitors have been developed against the enzyme. However, given the competitive nature of the available inhibitors, obtaining complete subfamily selectivity still presents an unresolved challenge. Here, we describe the discovery of a molecular scaffold for selective inhibition of FTO, which resulted from high throughput virtual screening targeted at FTO cryptic pockets. Analysis of the FTO-inhibitor interaction by solution NMR, molecular dynamics simulations, and enzyme kinetic assays shows that, differently from the FTO inhibitors developed so far, our molecule binds to a cryptic site between the FTO structural domains, and modulates the enzyme function non-competitively by perturbing the binding pose of the α-ketoglutarate and nucleic acid substrates. Since FTO is the only member of the AlkB family that presents multiple structural domains, we expect further development of this allosteric molecule to result in a new family of highly selective FTO inhibitors that can be used alone or in combination with pre-existing compounds to improve their potency and selectivity.

Indexed as

Alpha-Ketoglutarate-Dependent Dioxygenase FTOEnzyme InhibitorsBinding SitesDrug DiscoveryHumansKineticsMolecular Dynamics SimulationProtein BindingProtein DomainsAlpha-Ketoglutarate-Dependent Dioxygenase FTOEnzyme InhibitorsFTO protein, humanAlkB enzymesN(6)-methyladenosineNMRnucleic acid demethylaseprotein dynamics

Identifiers

PMID41354147
PMCPMC12709851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.